

## Special Issue

# The Role of RNAs in Cancers

### Message from the Guest Editor

Significant advances in RNA-based next-generation sequencing, single-cell transcriptomics, and third-generation long-read sequencing technologies have provided unprecedented depth and scope for understanding the role of RNA processing in diagnostics and therapies for undruggable targets in cancers. RNA-seq methods have led to the discovery of novel biomarkers in identifying differentially expressed miRNA, lncRNA, circRNA and fusion transcripts, enabling highly granular molecular characterizations of cancer subtypes that promise to actualize personalized medicine. Advances in separation science and nanotechnology platforms have helped to overcome some drawbacks of introducing RNA molecules into the body; eliciting immunogenicity and impermeability across membranes, promoting clinical trials for RNA-based therapeutics. A range of therapeutic options are being developed including: antisense oligonucleotide (ASO), small interfering RNA (siRNA), microRNA, aptamers, mRNA replacement and mRNA vaccines. This Special Issue reports on recent advances in RNA biology that will expand diagnostic and therapeutic capabilities for treating cancers.

---

### Guest Editor

Dr. Sanjive Qazi

Ares Pharmaceuticals, Saint Paul, MN, USA

---

### Deadline for manuscript submissions

closed (30 September 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

**Impact Factor 4.4**  
**CiteScore 8.8**  
**Indexed in PubMed**



[mdpi.com/si/159700](https://mdpi.com/si/159700)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)